Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21MT-1 | HER2amp | - | MG-132 | Proteasome | Proteasome | 14191.189 | uM | inf | inf | -0.1161 | -0.1161 | 0.0000 | 0.5482 | 0.5418 | 2.9704 | |
| 21MT-1 | HER2amp | - | Ribavirin | 15382.211 | uM | inf | inf | 0.9683 | 0.9683 | 0.0000 | 0.0416 | 0.0000 | 1.1714 | |||
| 184B5 | NM | Basal | Docetaxel | TUBB | TUBB | 12979.002 | uM | inf | inf | 0.7220 | 0.7220 | 0.0000 | 0.1667 | 0.1607 | 1.3178 | |
| 21MT-1 | HER2amp | - | Dichloroacetate | PDK | PDK | 13719.176 | uM | inf | inf | 0.9233 | 0.9233 | 0.0000 | 0.0596 | -0.2426 | 0.8672 | |
| 184B5 | NM | Basal | PS-1145 | IKK | NFKB | 5897.065 | uM | inf | inf | 0.9561 | 0.9561 | 0.0000 | 0.0500 | 0.3340 | 1.2996 | |
| 21MT-1 | HER2amp | - | MG-132 | Proteasome | Proteasome | 14191.189 | uM | inf | inf | -0.1161 | -0.1161 | 0.0000 | 0.5482 | 0.5418 | 2.9704 | |
| 184A1 | NM | Basal | Gefitinib | EGFR | ErbB | 9047.132 | uM | inf | inf | 0.4414 | 0.4414 | 0.0000 | 0.4398 | 0.3588 | 0.6985 | |
| 184A1 | NM | Basal | Trastuzumab | HER2 | ErbB | 9047.026 | uM | inf | inf | 0.2837 | 0.2837 | 0.0000 | 0.2170 | 0.0804 | 0.5972 | |
| 184B5 | NM | Basal | PS-1145 | IKK | NFKB | 5896.065 | uM | inf | inf | 0.9046 | 0.9046 | 0.0000 | 0.0309 | 0.3134 | 1.4978 | |
| 184A1 | NM | Basal | PD 98059 | MEK | MAPK | 12509.152 | uM | inf | inf | 0.7622 | 0.7622 | 0.0000 | 0.0595 | 0.4482 | 1.3755 | |
| 184B5 | NM | Basal | PD 98059 | MEK | MAPK | 12566.152 | uM | inf | inf | 0.9069 | 0.9069 | 0.0000 | 0.0066 | 0.4227 | 1.4827 | |
| 184A1 | NM | Basal | GSK923295 | CENPE | Kinesin | 9047.001 | uM | inf | inf | 0.0385 | 0.0385 | 0.0000 | 0.2510 | 0.5226 | 0.7701 | |
| 184B5 | NM | Basal | Sirolimus | MTOR | MTOR | 7789.068 | uM | inf | inf | -0.9304 | -0.9304 | 0.0000 | 1.0723 | 0.4470 | 0.3219 | |
| 184A1 | NM | Basal | GM6001 | MMP | MMP | 5895.096 | uM | inf | inf | 0.9763 | 0.9763 | 0.0000 | -0.0141 | -0.1057 | 1.4232 | |
| 184A1 | NM | Basal | (Z)-4-Hydroxytamoxifen | ESR1 | 9047.132 | uM | inf | inf | 0.4055 | 0.4055 | 0.0000 | 0.2074 | 0.3073 | 0.6985 | ||
| 184A1 | NM | Basal | Cetuximab | EGFR | ErbB | 7787.018 | uM | inf | inf | 0.4652 | 0.4652 | 0.0000 | 0.3838 | -0.0013 | 0.3791 | |
| 184A1 | NM | Basal | Vinorelbine | TUBB | TUBB | 7787.018 | uM | inf | inf | -0.9963 | -0.9963 | 0.0000 | 0.4831 | 0.4499 | 0.3791 | |
| 184A1 | NM | Basal | Dichloroacetate | PDK | PDK | 12684.176 | uM | inf | inf | 0.9148 | 0.9148 | 0.0000 | 0.0449 | 0.1851 | 1.3650 | |
| 184B5 | NM | Basal | GM6001 | MMP | MMP | 5897.096 | uM | inf | inf | 0.9590 | 0.9590 | 0.0000 | 0.0206 | -0.0228 | 1.2810 | |
| 184A1 | NM | Basal | Sirolimus | MTOR | MTOR | 7787.068 | uM | inf | inf | -0.2794 | -0.2794 | 0.0000 | 0.5821 | 0.4995 | 0.9562 | |
| 184A1 | NM | Basal | Glycyl-H-1152 | ROCK2 | 12509.169 | uM | inf | inf | 0.8820 | 0.8820 | 0.0000 | 0.0673 | 0.0092 | 1.5064 | ||
| 184A1 | NM | Basal | FTase Inhibitor I | Ftase | MAPK | 12509.167 | uM | inf | inf | 0.9988 | 0.9988 | 0.0000 | -0.0033 | -0.0009 | 1.4256 | |
| 184A1 | NM | Basal | PS-1145 | IKK | NFKB | 5895.065 | uM | inf | inf | 1.0031 | 1.0031 | 0.0000 | -0.0389 | -4.6402 | 1.3748 | |
| 600MPE | HR+ | Luminal | 2-deoxyglucose | 13091.177 | uM | inf | inf | 0.9504 | 0.9504 | 0.0000 | 0.3143 | 0.0580 | 0.7004 | |||
| 21NT | HER2amp | - | Ribavirin | 15383.211 | uM | inf | inf | 1.0074 | 1.0074 | 0.0000 | 0.0469 | 0.0000 | 1.0341 |